Metabolic impact of genetic and chemical ADP/ATP carrier inhibition in renal proximal tubule epithelial cells.

"Declarations Conflict of interestF.G.M.R. is co-inventor on patent EP2010/066792 ‘Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters’ assigned to Radboud University Medical Center and has conflict of interest through commercialization of ciPTEC models via Cell4Pharma. J.A.M.S. is the founding CEO and W.J.H.K. is an ad hoc scientific advisor of Khondrion BV, a Radboud University Medical Center spin-out company founded by J.A.M.S. Ethical approvalNot applicable. Consent to participateNot applicable. Consent for publicationNot applicable. Conflict of interest F.G.M.R. is co-inventor on patent EP2010/066792 ‘Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters’ assigned to Radboud University Medical Center and has conflict of interest through commercialization of ciPTEC models via Cell4Pharma. J.A.M.S. is the founding CEO and W.J.H.K. is an ad hoc scientific advisor of Khondrion BV, a Radboud University Medical Center spin-out company founded by J.A.M.S."

"Funding This research was supported by a grant from the Radboud University Medical Center (RIMLS 017-010a), awarded to T.J.J.S."